Considering outstanding PFS data in 1st Line of Kisqali+Fulvestrant, what would the most promising treatment combination in 1st Line be (CDK + AI or CDK + fulvestrant) ? How is this choice going to impact the treatment sequence strategy?

Should PFS outcomes drive treatment decisions in aBC when statistical significant improvement in OS is shown?

Kisqali Channel

00:07:05

How clinical relevance is assessed in randomized clinical trials?

Kisqali Channel

00:05:42

Is it easy to show overall survival in 1L HR+ HER2 – ABC?

Dr. Mattea Reinisch is talking on "Is it easy to show overall survival in 1L HR+ HER2 – ABC?"

Kisqali Channel

00:03:14

Talking about QoL, Kisqali also improved work productivity in M7, is that unique for Kisqali ?

Dr. Joanna Kufel-Grabowska is discussing on "When talking about QoL, Kisqali also improved work productivity in M7, is that unique for Kisqali?"

Kisqali Channel

00:03:08

All CDK4/6 have shown superior OS results?

Dr. Michelino De Laurentiis is speaking on "ALL CDK4/6 have shown superior OS results?"

Kisqali Channel

00:03:34

In M3 trial, when used in 1 Line Kisqali showed PFS of 33.4m, one of the highest ever seen with a CDK4/6 inhibitor. What is your thought on this?

Dr. Grazia Arpino is sharing her thoughts "In M3 trial, when used in 1 Line Kisqali showed PFS of 33.4m, one of the highest ever seen with a CDK4/6 inhibitor."

Kisqali Channel

00:02:23